Browse the evidence

Adherence to a low-carbohydrate diet (defined as ≤130g carbs/day or ≤25% calories) is sustainable long-term and nutritionally adequate, with high adherence rates reported in observational surveys.

To sustain a low-carbohydrate diet long-term, focus on the high satiety provided by fats and proteins. This natural hunger control makes the diet easier to maintain than calorie-restricted low-fat diets. Ensure your diet includes a variety of whole foods to meet all vitamin and mineral needs, as low-carb diets can be nutritionally complete.

The Swallowable Gastric Balloon Program (SGBP) combined with remote monitoring maintains 95% of total body weight loss (TBWL) one year after the device naturally passes, achieving a mean 13.2% TBWL.

If you are avoiding surgery, a swallowable gastric balloon combined with a strict remote monitoring program (app, scale, regular check-ins) can help you lose about 13% of your body weight and keep it off for at least a year after the device passes naturally. Success depends heavily on sticking to the behavioral program and using the provided digital tools for accountability.

Continuing lifestyle interventions (diet/exercise) after stopping AOMs does not prevent significant weight regain, as this subgroup also showed significant regain.

Even if you maintain a healthy diet and exercise routine, stopping anti-obesity medication is likely to lead to weight regain. The biological effects of the medication are significant, and lifestyle changes alone may not be enough to counteract the regain.

Relying solely on Fasting Plasma Glucose (FPG) for diagnosis misses a significant number of diabetes cases in Korean populations; OGTT or HbA1c is required for accurate diagnosis.

If you are Asian or have a lower body weight, a normal fasting blood sugar might not mean you are safe. You may have high blood sugar after eating. Ask your doctor about an OGTT or HbA1c test if you have risk factors.

HbA1c is a valid diagnostic criterion for diabetes (≥6.5%) in Korea, but it should not be used alone due to lower detection rates compared to combined FPG and OGTT.

HbA1c is a convenient test that doesn't require fasting, but it might miss diabetes if used alone. For the most accurate diagnosis, especially if you have conditions like anemia or kidney disease, combine it with fasting glucose or an OGTT.

GLP-1RAs may pose theoretical risks for individuals with restrictive eating disorders (e.g., Anorexia Nervosa) or high perfectionism, as appetite suppression can mask or reinforce rigid control and compensatory behaviors.

If you have a history of restrictive eating disorders or high perfectionism, GLP-1RAs require careful monitoring. The medication's ability to suppress appetite might mask or worsen restrictive behaviors, so prescribers should screen for these risks and watch for red flags like rapid weight loss or dizziness.

Pharmacotherapy may reduce bariatric surgical volume, particularly among patients with BMI 30-40, by providing a less invasive alternative.

If you have a BMI between 30 and 40, you now have a highly effective non-surgical option that may prevent the need for surgery. This is changing how doctors treat obesity.

Social Determinants of Health (SDoH), including socioeconomic status, neighborhood environment, and food access, are strongly associated with obesity prevalence and weight regain, independent of individual clinical factors.

Your environment matters. If you live in an area with limited access to healthy food or safe places to exercise, maintaining weight loss is significantly harder. Recognizing these external barriers can help you seek community resources or advocate for policy changes that support your health goals.

Self-managed lifestyle interventions (diet and exercise) are the primary initial weight loss strategy in China, but they result in low compliance and modest efficacy, leading to a high unmet need for anti-obesity medications (AOMs).

If you are in China and trying to lose weight, know that self-managed diet and exercise are the standard first steps, but they often fail due to low compliance. If lifestyle changes aren't working, it is not your fault; the current options have limitations. Discuss anti-obesity medications (AOMs) with your doctor, as new options are becoming available and are desired by both patients and physicians for better efficacy and safety.

Unsupervised resistance training in men with >3 years of experience fails to produce significant changes in fat-free mass or fat mass over 15 months.

If you have been lifting seriously for over three years and aren't seeing changes in muscle or fat despite training 3-5 times a week, your current self-directed approach has likely plateaued. You likely need professional guidance to systematically adjust training variables and nutrition, as self-regulation alone is insufficient for continued progress in advanced lifters.

MBS is associated with a higher risk of divorce or separation compared to the general population, particularly within the first five years post-surgery.

Be aware that your relationship dynamics may change significantly after surgery. While many relationships improve, there is a statistically higher risk of separation. Proactive communication and counseling can help navigate these changes.

Online marketing of GLP-1 receptor agonists as 'weight loss injections' creates unrealistic expectations and encourages off-label, non-medical use, posing significant public health risks.

Be skeptical of online content that promotes GLP-1 injections as 'weight loss injections' without mentioning medical indications, side effects, or the need for a prescription. These are serious medications for obesity management, not cosmetic shortcuts. Consult a healthcare provider to determine if you are a suitable candidate and to understand the risks and benefits.

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.

Maternal depression during pregnancy is significantly associated with an increased risk of gestational diabetes mellitus (GDM), suggesting that screening for depression may reduce GDM risk.

If you are pregnant, pay attention to your mental health. Depression during pregnancy is linked to a higher risk of gestational diabetes. Talk to your doctor about screening for depression to help protect your health and your baby's.

Public health reformulation of ultra-processed foods (UPF) fails to reduce population-level health harms because industry growth strategies (combatition, swotification, fashion spiral, demand-pumping) drive aggregate UPF consumption upward, negating individual product improvements.

Do not rely on 'reformulated' or 'light' UPFs as a health strategy. The food industry uses reformulation to maintain growth and market share, often increasing total consumption through strategies like smaller, more frequent portions ('portion paradoxes') and novelty marketing. To improve health, the most effective intervention is reducing the overall availability and consumption of the UPF category, not just tweaking its ingredients.

No single vegetable oil crop is inherently 'good' or 'bad'; the environmental and social impact depends entirely on the production system, trade practices, and local context.

Don't just look for 'palm oil-free' labels. Focus on supporting sustainable certification and production practices. No oil crop is inherently evil; the impact depends on how and where it is grown. Consider the broader environmental trade-offs of different oils.

Lower educational attainment is associated with higher prevalence of hypertension and diabetes, although this association becomes less pronounced after adjusting for other socioeconomic and demographic variables.

Education level is linked to health outcomes, with less education correlating with higher rates of hypertension and diabetes. Public health efforts should focus on providing accessible, easy-to-understand health information and care for individuals with lower educational attainment to reduce these disparities.

Access to obesity treatment in Canada is inequitable, with patients having high socioeconomic status being overrepresented in treatment programs compared to the general population of people with obesity, who are more likely to have lower socioeconomic status.

If you have a lower income, you may face barriers to accessing obesity treatment due to lack of insurance coverage. Advocate for yourself and your community for better access to affordable treatments. There are resources and programs that may help, and discussing financial concerns with your doctor is important.

Patients often learn about semaglutide and tirzepatide from social media and support groups rather than healthcare providers, who act as 'gatekeepers' rather than initial educators.

If you are interested in semaglutide or tirzepatide, do not assume your doctor will bring it up. You likely learned about it from social media or friends. Bring this information to your appointment, as providers may not be the initial source of this information but are necessary for safe access.

Tirzepatide use is strongly associated with a high frequency of dosing errors, particularly incorrect dose administration, which increases significantly over time and correlates with strong statistical safety signals.

If you are using tirzepatide, be aware that dosing errors are the most common side effect reported. The once-weekly schedule and mandatory dose increases can be confusing. Use a calendar or app to track your injections and strictly follow the titration steps to avoid mistakes.

Tirzepatide is associated with injection-site reactions, particularly pain, which are consistent with the class of GLP-1/GIP agonists and are typically mild and transient.

Injection site pain is a common side effect of tirzepatide. It is usually mild and goes away. Proper injection technique and counseling can help reduce this discomfort and help you stick with your treatment.

In routine clinical practice, sporadic individual dietary consultations do not significantly improve adherence to the Mediterranean diet in patients with type 2 diabetes.

If you have type 2 diabetes, simply attending a dietitian appointment once or twice a year is unlikely to change your diet significantly. To get results, you need intensive, ongoing support that provides concrete tools and food, not just sporadic advice. If you feel you already know how to eat well, focus on maintaining that consistency rather than seeking more general advice.

Phenotype-prioritized treatment selection (SGLT2i for HF/CKD, GLP-1RA for ASCVD/Obesity) optimizes outcomes and reduces polypharmacy compared to single-disease guidelines.

Ask your doctor for a 'phenotype-first' approach. Instead of treating each condition separately, choose drugs that protect your heart, kidneys, and metabolism all at once. This can simplify your medication list and reduce side effects.

Standardizing dietary interventions by objective diet quality (e.g., HEI-2020) while allowing variable diet types (cultural/personalized) improves adherence and external validity compared to fixed-type, one-size-fits-all interventions.

Focus on the quality of your diet (vegetables, fruits, legumes, nutrient density) rather than forcing yourself into a specific named diet (like Keto or strict Mediterranean) if it clashes with your culture or preferences. Use tools to measure your diet quality objectively. If you can maintain high quality while eating foods you culturally and personally enjoy, you will adhere better and see better long-term health outcomes.